Schwab, Nicholas; Schneider-Hohendorf, Tilman; Pignolet, Beatrice; Bucciarelli, Florence; Scandella, Lise; Ciron, Jonathan; Biotti, Damien; Lebrun-Frenay, Christine; Mathey, Guillaume; Clavelou, Pierre; Pelletier, Jean; Ostkamp, Patrick; Meinl, Ingrid; Windhagen, Susanne; Klotz, Luisa; Gross, Catharina C.; Meuth, Sven G.; Deisenhammer, Florian; Brassat, David; Wiendl, Heinz; Martinez, Maria; Heinzlef, Olivier; Zephir, Helene; Anne, Olivier; Audoin, Bertrand; Bensa, Caroline; Berger, Eric; Cabre, Philippe; Castelnovo, Giovanni; Collongues, Nicolas; Coustans, Marc; Creange, Alain; Dive, Dominique; Edan, Gilles; Fromont, Agnes; Gout, Olivier; Gouider, Riadh; Grimaud, Jerome; Hautecoeur, Patrick; Kiatkoswki, Arnaud; LePage, Emmanuelle; Marignier, Romain; Moreau, Thibault; Ouallet, Jean-Christophe; Papeix, Caroline; Rumbach, Lucien; Seeldrayers, Pierrette; Sennou, Ilham Slassi; Stankoff, Bruno; Tourbah, Ayman; Thouvenot, Eric und Vermersch, Patrick
(2019):
Prospective validation of the PML risk biomarker L-selectin and influence of natalizumab extended intervals.
In: Neurology, Bd. 93, Nr. 12: S. 550-554
Volltext auf 'Open Access LMU' nicht verfügbar.
- Dokument bearbeiten
